Genetic approaches to understanding the pathophysiology of complex human traits. Genetic approaches to understanding the pathophysiology of complex human traits, for example, hypertension, can complement physiologic analyses and are likely to improve our ability to treat or prevent the disease. A particularly useful approach is to perform linkage analysis with candidate genes using intermediate phenotypes. This has proven successful so far in identifying two genes involved in hypertension. The first was a fusion gene mutation which linked the regulatory region of the 11B-hydroxylase gene to the coding sequence for the protein of aldosterone synthetase. This mutant gene is responsible for the condition glucocorticoid-remediable aldostcronism (GRA). The intermediate phenotype used was increased levels of the adrenal steroids 18-oxo and hydroxycortisol. The gene for GRA was identified using a pedigree approach. It is likely, to identify other genes in hypertension, that the most appropriate population to be affected would be sib pairs, that is, sibling pairs who both have hypertension. In a recent study the angiotensinogen gene also was linked to hypertension in individuals who had severe or early onset hypertension. In addition, a variant of the angiotcnsinogen gene, substitution of threonine rather than methionine at codon 235, was specifically associated with hypertension. In a separate study, the T235 homozygote of the angiotensinogen gene was associated with the nonmodulating intermediate phenotype of essential hypertension. Since converting enzyme inhibitors appear to correct the specific defect underlying the elevated blood pressure in non-modulators, identification of the gene potentially associated with non-modulation raises the strong possibility that genetic screening will allow for more specific therapy.
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Despite intensive physiologic investigation, the major mechanisms responsible for a number of complex human diseases remains unclear, with the consequence that therapy is not necessarily directed toward the primary underlying causes. These complex diseases span a wide spectrum including hypertension, lipid disorders, Type II (non-insulin dependent) diabetes mellitus, depression, schizophrenia, anxiety states, and osteoporosis. There are at least three major obstacles which impede the identification of the primary defects in all of these diseases: (1) the lack of recognition that they are syndromes and not individual diseases;
(2) the variety of defects that could cause the final clinical read-out, for example, hypertension; and (3) the complex interplay of several physiologic systems which regulate the final end product of these syndromes, such as, elevated blood pressure, increased blood glucose, depression, osteoporosis, etc. The consequence of this interplay is that a wide variety of secondary events can be activated or suppressed when this final read-out is modified (that is, an increase in blood glucose or blood pressure) © 1994 by the International Society of Nephrology regardless of the cause, thereby masquerading as the primary defect.
Complementary to physiologic analysis are genetic approaches which are designed to identify mutations in genes which contribute to the development of the primary trait. Identification of such mutations would clearly establish where primary genetic abnormalities lie, thus providing a starting point from which to determine how normal physiology is deranged, resulting in the final clinical read-out.
Candidate gene
The general approach used to perform these types of studies is called "linkage analysis." It is derived from the actual process that is perfonned, that is, linking a particular trait to a specific gene [1] .
How difficult this process is depends on whether a specific candidate gene has been identified for the particular trait in question [2, 3] . If a candidate gene has been identified, then an assessment of the physical structure of the alleles involved in the production of its gene product can be determined, and the altered product identified. In some diseases with a dominant transmission, often there is a structural change within the coding region of the gene, which greatly simplifies the identification of an altered gene product. However, for complex traits this is unlikely to occur. Therefore, identifying heterozygosity in these alleles usually is accomplished by an assessment of structural differences in noncoding regions of the gene, for example, the 3' flanking region [3] . A careful search of the candidate gene usually will yield a number of different alleles all of which have a similar functional read-out, but each varies in the structural characteristics of other parts of the gene. The degree of distribution of these alleles in the general population determines the utility of a particular gene variant or marker as a genetic probe. Thus, if nearly everyone in the population under investigation has a particular allele for the candidate gene, this will not provide much information-the allele would not be very "informative." Ideally, a number of alleles are developed for a particular candidate gene, each of which would have a high degree of informativeness and, therefore, would be useful for genetic linkage studies.
General linkage analysis
When candidate genes are not known, then linkage studies can be performed using anonymous markers [1] . In this case one uses a series of markers which appropriately span the entire genome in an attempt to focus in on those areas in which a particular candidate gene may reside. This general linkage analysis is a much more arduous approach to evaluate genetic contributions, particularly to complex human traits, because of the large numbers of genes present in the human genome.
Intermediate phenotype
After the appropriate genetic approach is established, either general linkage or candidate gene, the next step is to determine which population will be studied and what characteristics of that population will be used to perform linkage to the gene(s) in question. The usual approach is to collect large extended pedigrees so that one can determine not only linkage to the gene(s) in question, but also potentially the inheritance patterns of the gene(s) identified to be associated with a specific trait. The power of these genetic analytical tools can be substantially increased if the population containing the distant phenotype (trait) can be subdivided into more homogenous subgroups, with individuals in such subgroups having an increased prevalence of a specific gene.
Furthermore, it is anticipated that use of these "intermediate" phenotypes will ultimately prove crucial in elucidating the physiologic mechanism(s) by which any identified relevant genetic variant imparts an effect. In this approach one not only requires the subject to have the distant phenotype, such as hypertension, but also to have a specific intermediate phenotype [4] . Having established this, linkage analysis with candidate genes then can be performed.
Glucocorticoid-remediable aldosteronism
An example of this approach is the identification of the gene responsible for a subset of the hypertensive population called glucocorticoid-remediable aldosteronism (GRA) [4, 5] . This is an autosomal-dominant trait characterized by hypertension, suppressed plasma renin activity, and control of aldosterone by ACTH rather than its usual secretagogues angiotensin II and potassium. In addition, patients with GRA secrete large amounts of the abnormal adrenal steroids 18-oxo-and hydroxycortisol.
Lifton, Dluhy and their colleagues took advantage of this specific biochemical trait-an intermediate phenotype-to identify members of a large pedigree who had GRA. Analysis of the physiology of GRA suggested the gene encoding aldosterone synthetasethe last step in the synthesis of aldosterone-as a candidate gene, which ultimately led to the demonstration of a mutation in this gene which precisely co-segregated with GRA in this pedigree. This mutation derives from an unequal crossing over between aldosterone synthetase and steroid 11-f3 hydroxylase (li-OHase) genes, resulting in a gene duplication in which the 5' regulatory region of il-hydroxylase is fused to the coding sequences for the protein, aldosterone synthetase. These results document the utility of combining intermediate phenotypes with the candidate gene strategy. It is worth noting that, as anticipated, even within the first pedigree studied not all hypertensive subjects had GRA.
As a consequence, had these investigators used hypertension rather than the biochemical trait (the intermediate phenotype) in linkage analysis, evidence for linkage would have been diminished by a factor of 100 (odds favoring linkage of 170,000:1 using intermediate phenotype as the trait; odds favoring linkage of 1700:1 using hypertension as the trait). When genetic effects are smaller than those seen in this extreme case, the anticipated loss of power from heterogeneity will be even larger.
Affected sibling pairs
The gene involved in GRA was identified by using a pedigree approach. For common traits such as obesity, hypertension, or Type II diabetes mellitus, taking this usual approach may be of limited value, since it is likely that new alleles contributing to an increase in the trait, such as, blood pressure, by a variety of mechanisms are introduced at each mating. Furthermore, in most cases it is unlikely that a mutation-a "bad" gene-will actually be found. A more likely scenario is the identification of minor variants of normal genes whose regulation or function has been modestly altered. It is this modestly-altered function in the presence of prolonged exposure to a certain environment that likely produces the disease. Thus, because genetic causes of these complex traits are likely to be multiple with varying degrees of penetrance and unknown inheritance, using affected sibling pairs for linkage studies to candidate genes is particularly appealing, provided two criteria are met: (1) relatively large numbers of subjects are studied; and (2) markers on the relative genes are highly informative as noted above [6] [7] [8] [9] . In the affected sibling pair approach, genetic and physiologic characteristics are obtained from siblings, both of whom have the distant phenotype, such as hypertension. Even linkage with anomalous genetic markers can be considered. However, there are two major drawbacks:
the need for even a larger study group to preserve analytical power and the reduced power when the assumed recombination fraction between the loci of the gene trait and marker is greater than zero. A major limitation in the application of the affected (for example, hypertensive) sibling pair approach is the relative lack of power compared to maximum likelihood analysis using classical Mendelian approaches. This limitation can be reduced and the power of this approach substantially increased if the heterogenous general trait population could be divided into more genetically homogenous subsets (intermediate phenotypes), as noted above. For example, in a study performed by Jeunemaitre et al designed to assess the contribution of variants in the angiotensinogen gene to hypertension, the results of the study varied depending on whether a general linkage approach was used or a more homogenous subset was analyzed [10] . Linkage was not consistently documented using hypertension alone as a trait. Such only occurred when a subset of the hypertensive population (that is, those with early-onset or more severe hypertension) was used. After establishing linkage, the next step was to search for variants in the angiotensinogen gene which are more specifically linked to the hypertension. These investigators found 15 such variants when they compared the structure of the gene in patients with hypertension and their normal population. One of these in which threonine (T) rather than methionine (M) was encoded at codon 235 proved to be significantly more prevalent in hypertensives than in controls. Dividing the population into those who were homozygotes for the T variant at codon 235 and those who were homozygous for the M variant, these investigators showed that T235 was associated with significantly elevated plasma angiotensinogen levels. These three lines of evidence, replicated in two independent samples, implicate a variant in the angiotensinogen gene in the pathogenesis of hypertension in this population.
Genetic research and treatment
Finally, what is the implication of genetic research to the treatment of patients with these complex human traits? The answer to this question can best be provided by a specific example: since the 1970s it has been known that sodium intake reciprocally modifies vascular and adrenal responses to angiotensin II (Ang II) [11, 121 . This reciprocal effect results in a more appropriate and specific response of the organism to changes in sodium intake without simultaneously producing changes in blood pressure. Recently, a series of studies have documented that some hypertensive patients have a defect in this dietary sodium effect. In the same patient, a decreased adrenal response to Ang II on a low salt diet and a decreased renal blood flow (RBF) response to Ang II on a high salt diet have been reported. These patients have been defined as "non-modulators" because sodium intake fails to modulate target tissue responsiveness to Ang II; those hypertensive patients whose responses fall into the range of normotensives are defined as "normal" modulators or simply "modulators" [13] [14] [15] . Of particular importance regarding the pathogenesis of the hypertension, non-modulators, in contrast to normal controls and modulators, fail to increase RBF in response to a high salt diet. Thus, sodium excretion is impaired resulting in sodium balance being achieved at a higher total body sodium and, consequently, a higher blood pressure due to the increased intravascular volume, that is, sodium-sensitive hypertension [14] [15] [16] . Based on studies performed on humans and in experimental animals, a defect in the regulation of the tissue renin-angiotensin system has been proposed to explain these abnormalities [14] [15] [16] [17] [18] .
Several lines of evidence suggest that the non-modulating trait is inherited, including familial aggregation of the non-modulating phenotype [19, 20] . Thus, non-modulation appears to be inherited form of essential hypertension comprising perhaps 25% of the total hypertensive population. Of therapeutic importance, the underlying defect producing the salt sensitivity in these patients is corrected by the administration of a converting enzyme inhibitor [14, 21] . If non-modulators could be easily identified, specific antihypertensive therapy could be offered. Accomplishing this using a physiologic approach is impractical given the profound impact dietary sodium intake has on the renal vascular and adrenal responses in normals. Recently we tested the hypothesis that the angiotensinogen variant associated with hypertension described above (T235) is a determinant of the non-modulating trait [22] . Our preliminary data strongly indicate that this is indeed the case, thereby suggesting that a simple, easy-to-measure genetic marker can identify individuals who are non-modulators. This discovery will have an immediate impact on the specificity of the antihypertensive therapy that can be offered to this subset of the hypertensive population. Furthermore, identification using this genetic marker early in the lives of individuals with strongly positive family histories of hypertension will identify nonmodulators in the pre-hypertensive phase, potentially allowing the implementation of specific and effective preventative programs to retard or even prevent the development of hypertension.
Thus, combining the powerful genetic tool of linkage analysis, particularly with candidate genes and the physiologic techniques embodied in assessing intermediate phenotypes is likely to prove more successful than either approach alone in determining the pathophysiology of complex common human traits such as Type II diabetes mellitus, hypertension, atherosclerosis, obesity, etc.
